Summary: Bavarian Nordic holds contracts totaling approximately $340 million for 2025, driven by vaccine demand
Summary: Bavarian Nordic’s mpox vaccine sales have declined post-outbreak, causing reduced revenue and highlighting its
Summary: WHO has declared a public health emergency due to an upsurge of mpox in
Summary: Bavarian Nordic specializes in vaccines for infectious diseases and immuno-oncology therapies, with Jynneos being
Summary: Bearish sentiment weighed heavily on the biotech industry and Bavarian Nordic A/S. There is
Summary: Bavarian Nordic has projected a strong year-over-year revenue growth for 2017. Stockpiling target of